Publication:
Coregulators determine androgen receptor activity in prostate cancer

dc.contributor.coauthorYavuz, Kerim
dc.contributor.coauthorLack, Nathan A.
dc.contributor.departmentSchool of Medicine
dc.contributor.departmentKUTTAM (Koç University Research Center for Translational Medicine)
dc.contributor.kuauthorFaculty Member, Lack, Nathan Alan
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.contributor.schoolcollegeinstituteResearch Center
dc.date.accessioned2025-09-10T04:57:01Z
dc.date.available2025-09-09
dc.date.issued2025
dc.description.abstractThe androgen receptor (AR) is the main driver of nearly all prostate cancer (PCa). It alters gene expression by binding to specific cis-regulatory elements on the DNA. Where the AR binds in the genome determines what genes are expressed. However, the AR cistrome is not static and dramatically changes during PCa initiation and progression to activate distinct transcriptional programs that fuel disease growth and therapeutic resistance. Emerging evidence suggests that these changes in DNA binding are not caused by chromatin accessibility but rather from interactions with AR coregulators. These proteins influence AR at every step of its activity and play a critical role in DNA binding and gene activation. These context-specific coregulator interactions can stabilize AR binding with DNA that has low-to moderate-affinity and also affect locus-spe- cific epigenetic modifications to promote transcription. Given their critical role in this process, alterations to coregulator proteins define the normal and oncogenic cistrome and profoundly affect AR-mediated gene transcription. In this review, we aim to provide a new perspective on the role of AR coregulators in transcriptional activity, how these interactions evolve through different stages of PCa and their potential as therapeutic targets in advanced disease.
dc.description.fulltextYes
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessGold OA
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuTÜBİTAK
dc.description.sponsorshipCancer Research Society [1314089]; Prostate Cancer Foundation of Canada; TÜBİTAK [221Z116, W81XWH-21-1-0234]; CIHR [PJT-173331]; NCI [P50CA097186]
dc.description.versionPublished Version
dc.description.volume45
dc.identifier.doi10.1042/BSR20253197
dc.identifier.eissn1573-4935
dc.identifier.embargoNo
dc.identifier.filenameinventorynoIR06409
dc.identifier.issn0144-8463
dc.identifier.issue8
dc.identifier.quartileN/A
dc.identifier.urihttps://doi.org/10.1042/BSR20253197
dc.identifier.urihttps://hdl.handle.net/20.500.14288/30212
dc.identifier.wos001555622100001
dc.language.isoeng
dc.publisherPortland Press Ltd
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofBioscience reports
dc.relation.openaccessYes
dc.rightsCC BY (Attribution)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectBiochemistry & Molecular Biology
dc.subjectCell Biology
dc.titleCoregulators determine androgen receptor activity in prostate cancer
dc.typeReview
dspace.entity.typePublication
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication91bbe15d-017f-446b-b102-ce755523d939
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
IR06409.pdf
Size:
1.36 MB
Format:
Adobe Portable Document Format